KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Cash Flow (2017 - 2026)

Aquestive Therapeutics has reported Net Cash Flow over the past 9 years, most recently at -$7.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 24.37% year-over-year to -$7.9 million; the TTM value through Dec 2025 reached $49.6 million, up 4.09%, while the annual FY2025 figure was $49.6 million, 4.09% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$7.9 million at Aquestive Therapeutics, down from $68.5 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $71.3 million in Q1 2024 and troughed at -$13.3 million in Q1 2022.
  • A 5-year average of $4.5 million and a median of -$3.0 million in 2021 define the central range for Net Cash Flow.
  • On a YoY basis, Net Cash Flow climbed as much as 18342.46% in 2024 and fell as far as 582.75% in 2024.
  • Year by year, Net Cash Flow stood at -$3.1 million in 2021, then surged by 374.65% to $8.6 million in 2022, then tumbled by 112.12% to -$1.0 million in 2023, then crashed by 507.37% to -$6.3 million in 2024, then decreased by 24.37% to -$7.9 million in 2025.
  • Business Quant data shows Net Cash Flow for AQST at -$7.9 million in Q4 2025, $68.5 million in Q3 2025, and -$8.1 million in Q2 2025.